Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Nanoviricides Inc (NNVC)
Nanoviricides Inc (NNVC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 15,666
  • Shares Outstanding, K 11,779
  • Annual Sales, $ 0 K
  • Annual Income, $ -8,590 K
  • 60-Month Beta 0.68
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.18
Trade NNVC with:

Options Overview Details

View History
  • Implied Volatility 235.24% ( -6.94%)
  • Historical Volatility 40.44%
  • IV Percentile 42%
  • IV Rank 13.54%
  • IV High 1,191.91% on 10/23/23
  • IV Low 85.44% on 03/28/23
  • Put/Call Vol Ratio 999.99
  • Today's Volume 11
  • Volume Avg (30-Day) 42
  • Put/Call OI Ratio 0.06
  • Today's Open Interest 330
  • Open Int (30-Day) 426

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/20
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.60
  • Growth Rate Est. (year over year) +166,600.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.0700 +24.30%
on 02/02/24
1.3600 -2.21%
on 02/26/24
+0.2600 (+24.30%)
since 01/26/24
3-Month
1.0001 +32.99%
on 12/29/23
1.3600 -2.21%
on 02/26/24
+0.3100 (+30.39%)
since 11/27/23
52-Week
1.0000 +33.00%
on 11/13/23
2.0000 -33.50%
on 07/11/23
+0.0700 (+5.56%)
since 02/27/23

Most Recent Stories

More News
The Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company’s Broad-Spectrum Antiviral Drug, Has Successfully Completed the First Part (Phase 1a), Reports NanoViricides

SHELTON, CT / ACCESSWIRE / November 28, 2023 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines...

NNVC : 1.3300 (unch)
NanoViricides Has Filed its Quarterly Report - NV-387 Broad-Spectrum Antiviral in Clinical Trials Has Additional Applications

SHELTON, CT / ACCESSWIRE / November 15, 2023 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that it has filed its Quarterly Report on Form 10-Q for the fiscal first quarter ending...

NNVC : 1.3300 (unch)
Broad-Spectrum Antiviral NV-387 (NV-CoV-2) in Phase 1a/1b Clinical Trial is Highly Effective in an Animal Model for MPox and Smallpox Drug Development

SHELTON, CT / ACCESSWIRE / November 14, 2023 / NanoViricides, Inc. (AMEX:NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines technology,...

NNVC : 1.3300 (unch)
NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 (NV-CoV-2) in Phase 1a/1b Clinical Trial is Highly Active Against Coronaviruses as well as RSV

SHELTON, CT / ACCESSWIRE / October 16, 2023 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that it has filed its Annual Report on Form 10-K for the fiscal year ending June 30, 2023...

NNVC : 1.3300 (unch)
NanoViricides, Inc. to Present at the Partnership Opportunities in Drug Delivery Conference in Boston on October 16, 2023 at 6:07pm ET

SHELTON, CT / ACCESSWIRE / October 12, 2023 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), announces that the Company's President, Dr. Anil Diwan, will be presenting a talk in person at the...

NNVC : 1.3300 (unch)
The Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company’s Broad-Spectrum Antiviral Drug, is Progressing Successfully, Reports NanoViricides

SHELTON, CT / ACCESSWIRE / August 21, 2023 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines...

NNVC : 1.3300 (unch)
Company’s Broad-Spectrum Antiviral NV-387 Has Demonstrated Excellent Effectiveness in RSV in a Lethal Lung Disease Animal Model, Reports NanoViricides

SHELTON, CT / ACCESSWIRE / July 11, 2023 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines technology,...

NNVC : 1.3300 (unch)
Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs

SHELTON, CO / ACCESSWIRE / July 6, 2023 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") reports that the clinical trial of its broad-spectrum antiviral drug NV-CoV-2 is progressing satisfactorily....

NNVC : 1.3300 (unch)
NanoViricides, Inc. to Present at the BIO International Convention in Boston on June 5th, 2023 at 3:15pm ET

SHELTON, CT / ACCESSWIRE / May 31, 2023 / NanoViricides, Inc. (NYSE Amer:NNVC) (the "Company"), announces that the Company's President, Dr. Anil Diwan, will be presenting a talk in person at the BIO International...

NNVC : 1.3300 (unch)
NanoViricides Has Filed its Quarterly Report - Clinical Trials of Broad-Spectrum COVID Drug About to Begin

SHELTON, CT / ACCESSWIRE / May 16, 2023 / NanoViricides, Inc. (NYSE Amer:NNVC) (the "Company"), reports that it has filed its Quarterly Report on Form 10-Q for the fiscal third quarter ending March 31,...

NNVC : 1.3300 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakening short term outlook on maintaining the current direction.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

NanoViricides, Inc. is a development stage company focused on creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. It also focuses on the development...

See More

Key Turning Points

3rd Resistance Point 1.4033
2nd Resistance Point 1.3767
1st Resistance Point 1.3533
Last Price 1.3300
1st Support Level 1.3033
2nd Support Level 1.2767
3rd Support Level 1.2533

See More

52-Week High 2.0000
Fibonacci 61.8% 1.6180
Fibonacci 50% 1.5000
Fibonacci 38.2% 1.3820
Last Price 1.3300
52-Week Low 1.0000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar